During the recent session, SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s traded shares were 1.25 million, with the beta value of the company hitting 2.33. At the last check today, the stock’s price was $1.33, reflecting an intraday gain of 1.15% or $0.02. The 52-week high for the SLS share is $1.91, that puts it down -43.61 from that peak though still a striking 62.41% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $74.56M, and the average intraday trading volume over the past 10 days was 2.14 million shares, and the average trade volume was 1.48 million shares over the past three months.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) trade information
SELLAS Life Sciences Group Inc (SLS) registered a 1.15% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.15% in intraday trading to $1.33, hitting a weekly high. The stock’s 5-day price performance is 28.64%, and it has moved by 26.19% in 30 days. Based on these gigs, the overall price performance for the year is -18.21%. The short interest in SELLAS Life Sciences Group Inc (NASDAQ:SLS) is 5.18 million shares and it means that shorts have 3.9 day(s) to cover.
SELLAS Life Sciences Group Inc (SLS) estimates and forecasts
Statistics show that SELLAS Life Sciences Group Inc has outperformed its competitors in share price, compared to the industry in which it operates. SELLAS Life Sciences Group Inc (SLS) shares have gone down -9.86% during the last six months, with a year-to-date growth rate more than the industry average at 35.07% against 13.70. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 55.30% this quarter and then jump 35.50% in the quarter after that. An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 61.44%. While earnings are projected to return 14.93% in 2024.
SLS Dividends
SELLAS Life Sciences Group Inc is due to release its next quarterly earnings between May 09 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s Major holders
SELLAS Life Sciences Group Inc insiders own 0.51% of total outstanding shares while institutional holders control 10.68%, with the float percentage being 10.73%. Alyeska Investment Group, L.p. is the largest shareholder of the company, while 39 institutions own stock in it. As of Jun 29, 2023, the company held over 1.25 million shares (or 4.41% of all shares), a total value of $1.96 million in shares.
The next largest institutional holding, with 0.95 million shares, is of Vanguard Group Inc’s that is approximately 3.34% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $1.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of SELLAS Life Sciences Group Inc (SLS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.59 million shares. This amounts to just over 2.09 percent of the company’s overall shares, with a $0.93 million market value. The same data shows that the other fund manager holds slightly less at 0.32 million, or about 1.12% of the stock, which is worth about $0.5 million.
